CIK 0002044725
- Emerging growth company
Evommune, Inc.
Sign in to watch- Ticker
- EVMN
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 850742575
- Phone
- +1 650-223-7745
- Business address
- 1891 PAGE MILL RD, PALO ALTO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +691,441 | 691,441 | ||
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +1,157,096 | $16.00 | $18.5M | 2,674,425 |
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +92,904 | $16.00 | $1.5M | 784,345 |
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series C Preferred Stock | −12,924,620 | 0 | ||
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series C Preferred Stock | −5,889,699 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion | +1,441,032 | 1,441,032 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion | +1,632,441 | 1,632,441 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion | +294,502 | 294,502 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series Seed Preferred Stock | −7,145,647 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series Seed Preferred Stock | −3,572,816 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series A Preferred Stock | −2,582,243 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series A Preferred Stock | −7,230,283 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series B Preferred Stock | −1,895,260 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series B Preferred Stock | −2,104,740 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series C Preferred Stock | −313,571 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series C Preferred Stock | −313,571 | 0 | ||
| 2025-11-07 | Pivotal bioVenture Partners Fund I, L.P. Director | Conversion · Series C Preferred Stock | −2,508,575 | 0 | ||
| 2025-11-05 | Patel Jeegar Pravinkumar Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +179,619 | 179,619 | ||
| 2025-11-05 | Drew Janice Suzann EVP, Operations | Grant or award · Employee Stock Option (Right to Buy) | +231,274 | 231,274 | ||
| 2025-11-05 | Carver Kyle Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +279,408 | 279,408 |
Page 7 of 8 · 145 trades